Trial · NCT07908628

Effectiveness of Internet-based Unified Protocol (iUP) for Emotional Problems: A Randomized Controlled Trial

NCT07908628, Not applicable, Not yet recruiting, New Life Psychiatric Rehabilitation Association

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effectiveness of Internet-based Unified Protocol (iUP) for Emotional Problems: A Randomized Controlled Trial. Trials, record NCT07908628. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07908628

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effectiveness of Internet-based Unified Protocol (iUP) for Emotional Problems: A Randomized Controlled Trial
NCT number: NCT07908628
Status: Not yet recruiting
Phases: Not applicable
Enrollment: 78 participants, estimated
Lead sponsor: New Life Psychiatric Rehabilitation Association
Conditions: Depression - Major Depressive Disorder, Generalised Anxiety Disorder, Anxiety Disorder (Panic Disorder or GAD), Depressive and Anxiety Disorders
Interventions: Internet-based Unified Protocol (iUP), Waitlist Control Group
First posted: 2026-11-02
Last updated: 2026-11-02

Source ClinicalTrials.gov

Registered outcomes17

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Patient Health Questionnaire-9 (PHQ-9)	Intake, weekly during the 14-week intervention period (Weeks 1 - 14), and at 1-, 2-, 3-, 6-, and 12-month follow-ups after the end of the intervention.	Patient Health Questionnaire-9 (PHQ-9) is a 9-item self-report questionnaire designed to screen for depression and assess its severity in both clinical and research settings. Participants rate the frequency of depressive symptoms over the past two weeks on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 27, with higher scores indicating greater depression severity. In a Hong Kong community sample, the PHQ-9 demonstrated good internal consistency (α = .82) and test-retest reliability (r = .76) (Yu et al., 2012).
Primary	Generalized Anxiety Disorder-7 (GAD-7)	Intake, weekly during the 14-week intervention period (Weeks 1 - 14), and at 1-, 2-, 3-, 6-, and 12-month follow-ups after the end of the intervention.	Generalized Anxiety Disorder-7 (GAD-7) is a 7-item self-report questionnaire designed to screen for anxiety and assess its severity in both clinical and research settings. Participants rate the frequency of anxiety symptoms over the past two weeks on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 21, with higher scores indicating greater anxiety severity. In a sample of Chinese medical university students, the GAD-7 demonstrated high internal consistency (α = .93; Zhang et al., 2021).
Secondary	Taiwan version of Penn State Worry Questionnaire (T-PSWQ)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Taiwan version of Penn State Worry Questionnaire (T-PSWQ) The Penn State Worry Questionnaire (PSWQ) is a 16-item self-report measure designed to assess pathological or trait-based worry (Meyer et al., 1990). In the current study, the Taiwan version of the PSWQ will be used. Participants rate how typical or characteristic each item is of them on a 5-point Likert scale ranging from 1 (not at all) to 5 (very typical of me). Total scores range from 16 to 80, with higher scores indicating greater levels of worry. In a sample of university students, the Taiwan version of the PSWQ demonstrated high internal consistency (α = .88; Teng et al., 2015).
Secondary	Liebowitz Social Anxiety Scale (LSAS)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Liebowitz Social Anxiety Scale (LSAS) is a 24-item self-report tool designed to assess fear and avoidance associated with Social Anxiety Disorder (SAD). In the current study, the Chinese version of the LSAS will be used. Participants rate each item on a 4-point Likert scale ranging from 0 (none) to 3 (severe) for fear and from 0 (never) to 3 (usually) for avoidance. Total scores range from 0 to 144, with higher scores indicating greater social anxiety. The Chinese version of the LSAS has demonstrated robust internal consistency (α \> .90) and high test-retest reliability (r \> .75) (He \& Zhang, 2004).
Secondary	Chinese version of Obsessive-Compulsive Inventory-Revised (C-OCI-R)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Chinese version of Obsessive-Compulsive Inventory-Revised (C-OCI-R) Obsessive-Compulsive Inventory-Revised (OCI-R) is an 18-item self-report questionnaire designed to measure the severity of obsessive-compulsive symptoms (Foa et al., 2022). In the current study, the Chinese version of the scale (C-OCI-R) will be used. Participants rate each item on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). Total scores range from 0 to 72, with higher scores indicating greater severity of obsessive-compulsive symptoms. The C-OCI-R has demonstrated excellent internal consistency (α = .92) and excellent test-retest reliability (ρ = .96; Hon et al., 2019).
Secondary	Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	The Posttraumatic Stress Disorder Checklist for DSM-5 (PCL-5) is a 20-item self-report questionnaire designed to assess the severity of posttraumatic stress disorder (PTSD) symptoms according to DSM-5 criteria (Blevins et al., 2015). In the current study, the Chinese version of the PCL-5 will be used. Participants rate each item on a 5-point Likert scale ranging from 0 (not at all) to 4 (extremely). Total scores range from 0 to 80, with higher scores indicating greater PTSD symptom severity. The Chinese version of the PCL-5 has demonstrated excellent internal consistency (α = .95; Fung et al., 2019).
Secondary	Insomnia Severity Index (ISI)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Insomnia Severity Index (ISI) is a 7-item self-report questionnaire developed to evaluate the nature, severity, and impact of insomnia. In the current study, the Chinese version of the scale (ISI-C) will be used. Participants rate each item on a 5-point Likert scale ranging from 0 (no problem) to 4 (very severe problem). Total scores range from 0 to 28, with higher scores indicating greater insomnia severity. The ISI-C has demonstrated excellent internal consistency (α = .94; Yang et al., 2009).
Secondary	Short Health Anxiety Inventory (SHAI)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Short Health Anxiety Inventory (SHAI) is an 18-item self-report questionnaire designed to measure health anxiety. In the current study, the Chinese version of the scale (CSHAI) will be used. Participants rate each item on a 4-point scale ranging from 0 to 3. Total scores range from 0 to 54, with higher scores indicating greater health anxiety. The CSHAI has demonstrated good internal consistency (α = .74; Zhang et al., 2015).
Secondary	Brief Experiential Avoidance Questionnaire (BEAQ)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Brief Experiential Avoidance Questionnaire (BEAQ) is a 15-item self-report questionnaire designed to assess individuals' experiential avoidance (Gámez et al., 2014). In the current study, the Chinese version of the BEAQ will be used. Participants rate each item on a 6-point Likert scale ranging from 1 (strongly disagree) to 6 (strongly agree). Total scores range from 15 to 90, with higher scores indicating greater experiential avoidance. The BEAQ has demonstrated good internal consistency (α \> .80) across clinical, student, and community samples (Gámez et al., 2014). The Chinese version of the BEAQ has demonstrated good internal consistency (α = .85; Lo et al., 2023).
Secondary	Difficulties in Emotion Regulation Scale-16 (DERS-16)	Weeks 1, 5 and 14 during the 14-week intervention period, as well as at 3- and 12-month follow-ups after the end of the intervention.	Difficulties in Emotion Regulation Scale-16 (DERS-16) is a 16-item self-report questionnaire designed to assess difficulties with emotion regulation. In the current study, the Chinese version of the DERS-16 will be used. Participants rate each item on a 5-point Likert scale ranging from 1 (almost never) to 5 (almost always). Total scores range from 16 to 80, with higher scores indicating greater difficulties in emotion regulation. The DERS-16 has demonstrated excellent internal consistency (α \> .90) and good test-retest reliability (r = .85; Bjureberg et al., 2015). The Chinese version of DERS-16, which has shown excellent internal consistency (α = .90) and good test-retest reliability (r = .84; Li et al., 2018).

1 to 10 of 17Source ClinicalTrials.gov

See all 17 registered outcomes

Outcomes0

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

None in this release.

Results by group0

Each measurement the trial posted, group by group, in the words and numbers it posted.

None in this release.

Participant flow0

How many started, completed or left each group, period by period.

None in this release.

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals0

The totals the trial posted for each group.

None in this release.

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33159447	BACKGROUND

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT07908628

GET https://conductscience.org/api/trials/v1/NCT07908628/registered

API reference For AI assistants